MicroRNA-34c Downregulation Ameliorates Amyloid-β-Induced Synaptic Failure and Memory Deficits by Targeting VAMP2

Journal of Alzheimer's Disease

Volumn 48, Issue 3, 2015, Pages 673-686

  Hu, Shunze ^a,b   Wang, Huan ^a   Chen, Kun ^a   Cheng, Peng ^a   Gao, Shutao ^a   Liu, Jian ^a   Li, Xiao ^a   Sun, Xuying ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b Hubei Provincial Maternal and Children's Hospital   (China)

Author keywords

Alzheimer's disease; amyloid ; miR 34c; VAMP2

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; MICRORNA; MICRORNA 34C; SYNAPTOBREVIN 2; UNCLASSIFIED DRUG; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); MIRN34 MICRORNA, HUMAN; MIRN34 MICRORNA, MOUSE; MIRN34 MICRORNA, RAT; PEPTIDE FRAGMENT;

AMNESIA; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; EMBRYO; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUCIFERASE ASSAY; MOUSE; NONHUMAN; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN RNA BINDING; PROTEIN TARGETING; RAT; SYNAPTIC TRANSMISSION; UPREGULATION; WESTERN BLOTTING; ANIMAL; C57BL MOUSE; CELL SURVIVAL; HEK293 CELL LINE; HIPPOCAMPUS; MAZE TEST; MEMBRANE POTENTIAL; MEMORY DISORDER; METABOLISM; PHYSIOLOGY; SPRAGUE DAWLEY RAT; SYNAPSE; TISSUE CULTURE TECHNIQUE; TUMOR CELL LINE;

AMYLOID BETA-PEPTIDES; ANIMALS; CELL LINE, TUMOR; CELL SURVIVAL; DOWN-REGULATION; HEK293 CELLS; HIPPOCAMPUS; HUMANS; MAZE LEARNING; MEMBRANE POTENTIALS; MEMORY DISORDERS; MICE, INBRED C57BL; MICRORNAS; PEPTIDE FRAGMENTS; RATS, SPRAGUE-DAWLEY; SYNAPSES; TISSUE CULTURE TECHNIQUES; VESICLE-ASSOCIATED MEMBRANE PROTEIN 2;

EID: 84943767091     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-150432     Document Type: Article

References (35)

1. Haass C, Selkoe DJ (2007) Soluble protein oligomers in neurodegeneration: Lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol 8, 101-112.
2. Mount C, Downton C (2006) Alzheimer disease: Progress or profit? Nat Med 12, 780-784.
3. Xu Y, Cao DH, Wu GM, Hou XY (2014) Involvement of P38MAPK activation by NMDA receptors and non-NMDA receptors in amyloid-beta peptide-induced neuronal loss in rat hippocampal CA1 and CA3 subfields. Neurosci Res 85, 51-57.
4. Zempel H, Luedtke J, Kumar Y, Biernat J, Dawson H, Mandelkow E, Mandelkow EM (2013) Amyloid-beta oligomers induce synaptic damage via Tau-dependent microtubule severing by TTLL6 and spastin. EMBO J 32, 2920-2937.
5. Isono T, Yamashita N, Obara M, Araki T, Nakamura F, Kamiya Y, Alkam T, Nitta A, Nabeshima T, Mikoshiba K, Ohshima T, Goshima Y (2013) Amyloid-beta(2)(5)(-)(3)(5) induces impairment of cognitive function and long-term potentiation through phosphorylation of collapsin response mediator protein 2. Neurosci Res 77, 180-185.
6. Terry RD (2000) Cell death or synaptic loss in Alzheimer disease. J Neuropathol Exp Neurol 59, 1118-1119.
7. Fang Q, Lindau M (2014) How could SNARE proteins open a fusion pore? Physiology (Bethesda) 29, 278-285.
8. Martens S, Kozlov MM, McMahon HT (2007) How synaptotagmin promotes membrane fusion. Science 316, 1205-1208.
9. Watanabe D (2010) [Conditional cell targeting and reversible synapse silencing to study neural circuits]. Brain Nerve 62, 255-262.
10. Pham E, Crews L, Ubhi K, Hansen L, Adame A, Cartier A, Salmon D, Galasko D, Michael S, Savas JN, Yates JR, Glabe C, Masliah E (2010) Progressive accumulation of amyloid-beta oligomers in Alzheimer's disease and in amyloid precursor protein transgenic mice is accompanied by selective alterations in synaptic scaffold proteins. FEBS J 277, 3051-3067.
11. Chen J, Herrup K (2012) Glutamine acts as a neuroprotectant against DNA damage, beta-amyloid and H2O2-induced stress. PLoS One 7, e33177.
12. Nenov MN, Laezza F, Haidacher SJ, Zhao Y, Sadygov RG, Starkey JM, Spratt H, Luxon BA, Dineley KT, Denner L (2014) Cognitive enhancing treatment with a PPARgamma agonist normalizes dentate granule cell presynaptic function in Tg2576 APP mice. J Neurosci 34, 1028-1036.
13. Russell CL, Semerdjieva S, Empson RM, Austen BM, Beesley PW, Alifragis P (2012) Amyloid-beta acts as a regulator of neurotransmitter release disrupting the interaction between synaptophysin and VAMP2. PLoS One 7, e43201.
14. Parodi J, Sepulveda FJ, Roa J, Opazo C, Inestrosa NC, Aguayo LG (2010) Beta-amyloid causes depletion of synaptic vesicles leading to neurotransmission failure. J Biol Chem 285, 2506-2514.
15. Chauhan NB, Siegel GJ (2002) Reversal of amyloid beta toxicity in Alzheimer's disease model Tg2576 by intraventricular antiamyloid beta antibody. J Neurosci Res 69, 10-23.
16. Muller M, Kuiperij HB, Claassen JA, Kusters B, Verbeek MM (2014) MicroRNAs in Alzheimer's disease: Differential expression in hippocampus and cell-free cerebrospinal fluid. Neurobiol Aging 35, 152-158.
17. Kim VN, Han J, Siomi MC (2009) Biogenesis of small RNAs in animals. Nat Rev Mol Cell Biol 10, 126-139.
18. Bartel DP (2004) MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell 116, 281-297.
19. Wei C, Thatcher EJ, Olena AF, Cha DJ, Perdigoto AL, Marshall AF, Carter BD, Broadie K, Patton JG (2013) miR-153 regulates SNAP-25, synaptic transmission, and neuronal development. PLoS One 8, e57080.
20. Rodriguez-Ortiz CJ, Baglietto-Vargas D, Martinez-Coria H, LaFerla FM, Kitazawa M (2014) Upregulation of miR-181 decreases c-Fos and SIRT-1 in the hippocampus of 3xTg-AD mice. J Alzheimers Dis 42, 1229-1238.
21. Sun XY, Wei YP, Xiong Y, Wang XC, Xie AJ, Wang XL, Yang Y, Wang Q, Lu YM, Liu R, Wang JZ (2012) Synaptic released zinc promotes tau hyperphosphorylation by inhibition of protein phosphatase 2A (PP2A). J Biol Chem 287, 11174-11182.
22. Brandeis R, Brandys Y, Yehuda S (1989) The use of the Morris water maze in the study of memory and learning. Int J Neurosci 48, 29-69.
23. Sholl DA (1953) Dendritic organization in the neurons of the visual and motor cortices of the cat. J Anat 87, 387-406.
24. Zovoilis A, Agbemenyah HY, Agis-Balboa RC, Stilling RM, Edbauer D, Rao P, Farinelli L, Delalle I, Schmitt A, Falkai P, Bahari-Javan S, Burkhardt S, Sananbenesi F, FischerA(2011) microRNA-34c is a novel target to treat dementias. EMBO J 30, 4299-4308.
25. Wahlquist C, Jeong D, Rojas-Munoz A, Kho C, Lee A, Mitsuyama S, van Mil A, Park WJ, Sluijter JP, Doevendans PA, Hajjar RJ, Mercola M (2014) Inhibition of miR-25 improves cardiac contractility in the failing heart. Nature 508, 531-535.
26. Shi J, Wang Q, Johansson JU, Liang X, Woodling NS, Priyam P, Loui TM, Merchant M, Breyer RM, Montine TJ, Andreasson K (2012) Inflammatory prostaglandin E2 signaling in a mouse model of Alzheimer disease. Ann Neurol 72, 788-798.
27. Tannenberg RK, Scott HL, Tannenberg AE, Dodd PR (2006) Selective loss of synaptic proteins in Alzheimer's disease: Evidence for an increased severity with APOE varepsilon4. Neurochem Int 49, 631-639.
28. Honer WG, Barr AM, Sawada K, Thornton AE, Morris MC, Leurgans SE, Schneider JA, Bennett DA (2012) Cognitive reserve, presynaptic proteins and dementia in the elderly. Transl Psychiatry 2, e114.
29. Corney DC, Flesken-Nikitin A, Godwin AK, Wan GW, Nikitin AY (2007) MicroRNA-34b and MicroRNA-34c are targets of p53 and cooperate in control of cell proliferation and adhesion-independent growth. Cancer Res 67, 8433-8438.
30. Kumamoto K, Spillare EA, Fujita K, Horikawa I, Yamashita T, Appella E, Nagashima M, Takenoshita S, Yokota J, Harris CC (2008) Nutlin-3a activates p53 to both down-regulate inhibitor of growth 2 and up-regulate mir-34a, mir-34b, and mir-34c expression, and induce senescence. Cancer Res 68, 3193-3203.
31. Haramati S, Navon I, Issler O, Ezra-Nevo G, Gil S, Zwang R, Hornstein E, Chen A (2011) MicroRNA as repressors of stress-induced anxiety: The case of amygdalar miR-34. J Neurosci 31, 14191-14203.
32. Bhatnagar S, Chertkow H, Schipper HM, Yuan Z, Shetty V, Jenkins S, Jones T, Wang E (2014) Increased microRNA-34c abundance in Alzheimer's disease circulating blood plasma. Front Mol Neurosci 7, 2.
33. Mesulam MM (1999) Neuroplasticity failure in Alzheimer's disease: Bridging the gap between plaques and tangles. Neuron 24, 521-529.
34. Ittner LM, Gotz J (2011) Amyloid-beta and tau-a toxic pas de deux in Alzheimer's disease. Nat Rev Neurosci 12, 65-72.
35. Pennuto M, Bonanomi D, Benfenati F, Valtorta F (2003) Synaptophysin I controls the targeting of VAMP2/synaptobrevin II to synaptic vesicles. Mol Biol Cell 14, 4909-4919.